Cargando…
Radioiodine Therapy of Graves' Disease and the Uptake Paradox
PURPOSE OF THE STUDY: Radioiodine ((131)I) therapy is approved and well-accepted modality for the treatment of hyperthyroidism. The dosage of (131)I for successful treatment is based on many factors; however, an objective tool to determine the dose was missing. In a retrospective study, we found tha...
Autores principales: | Malapure, Sumeet Suresh, Mukherjee, Anirban, Bal, Chandrasekar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958960/ https://www.ncbi.nlm.nih.gov/pubmed/31949364 http://dx.doi.org/10.4103/ijnm.IJNM_158_19 |
Ejemplares similares
-
Radioiodine therapy and Graves’ disease – Myths and reality
por: Plazinska, Maria Teresa, et al.
Publicado: (2020) -
Radioiodine therapy in patients with Graves’ disease and the effects of prior carbimazole therapy
por: Karyampudi, Arun, et al.
Publicado: (2014) -
Evaluation of CYFRA 21.1 as a Dedifferentiation Marker of Advanced Thyroid Cancer
por: Malapure, Sumeet Suresh, et al.
Publicado: (2020) -
Radioiodine Therapy-Induced Conversion of Toxic Adenoma to Graves’ Disease
por: Rehman, Anis, et al.
Publicado: (2020) -
Prognostic factor analysis in 325 patients with Graves’ disease treated with radioiodine therapy
por: Yang, Danrong, et al.
Publicado: (2018)